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80 The Journal of Thoracic and Cardiobjective: Accumulating evidence reveals that statins possess direct anti-inflammatory
roperties through inhibition of proinflammatory cytokine and chemokine secretion
n addition to their antioxidant effects, which may contribute to amelioration of
schemia-reperfusion injury. This study tested the hypothesis that perioperative
reatment of simvastatin suppresses the cardiac isograft ischemia-reperfusion injury
y down-regulation of CC chemokine receptor-2 expression in an inbred rat model
f cardiac transplantation.
ethods: Donor hearts from Lewis rats were heterotopically transplanted to Lewis
at recipients. Recipients were orally treated with simvastatin (1 mg/kg) or vehicle
very morning 3 days before the surgery until the harvest day. Rats were killed at
hours and at 1, 3, and 7 days after transplantation. Injury was assessed by infarct
ize measurement, histologic and immunohistochemical examination, and intragraft
yeloperoxidase activity assay. Monocyte chemoattractant protein-1 levels in se-
um and graft were analyzed by enzyme-linked immunosorbent assay, and intragraft
C chemokine receptor-2 expression was measured by quantitative real-time poly-
erase chain reaction.
esults: The infarct size and macrophage infiltration were all significantly reduced
n the simvastatin-treated group compared with those of the control group at 1 day
fter transplantation. Neutrophil accumulation was significantly suppressed until 3
ays after transplantation, whereas myeloperoxidase activity had been significantly
iminished at 1 day after transplantation. Both monocyte chemoattractant protein-1
oncentrations in serum and graft were remarkably decreased at 6 hours after
ransplantation. Intragraft CC chemokine receptor-2 expression was also down-
egulated at 1 day and 3 days after transplantation.
onclusions: Perioperative treatment of simvastatin could suppress the isograft
schemia-reperfusion injury through retarding intragraft monocyte chemoattractant
rotein-1 accumulation and CC chemokine receptor-2 expression.
schemia-reperfusion injury (IRI) is of paramount importance to organ trans-
plantation and is a major determinant of early graft dysfunction.1 If over-
whelmed, IRI might exert continuous and deleterious effects on allografts.uring IRI, secretion of intragraft proinflammatory cytokines, chemokines, and
vascular Surgery ● September 2007
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TXdhesion molecules is increased, and such mediators could
romote adhesion and migration of alloreactive T lympho-
ytes, ultimately triggering the acute rejection process.2 In
ddition, several earlier studies have also demonstrated that
he extent or duration of IRI is positively correlated with the
egree of cardiac allograft vasculopathy and allograft long-
erm survival.3,4 Therefore, maximal reduction of IR
hould markedly decrease the rates of acute and chronic
ejection and prolong the survival of grafts.
Leukocyte recruitment is essential for the development
f IRI and involves graft endothelia up-regulation of adhe-
ion molecules, selectins, and especially chemokines.1 Over
he past years, chemokines and their receptors have become
he subject of intensive investigations. Chemokine expres-
ion is a prominent feature of the IRI inflammatory response
nd may play an important role in leukocyte recruitme5,6
ne of the best-studied CC chemokines, monocyte che-
oattractant protein-1 (MCP-1), is reported to be the key
olecule in terms of chemotaxis and activation of macro-
hages, with the CC chemokine receptor-2 (CCR2) as its
ajor receptor. MCP-1 up-regulation has been observed in
xperimental myocardial infarction of canines, rats, and
ice.7 Growing evidence indicates that blockade of MCP
CR2 signaling could markedly retard macrophage infiltra-
ion and activation in IRI. For example, recent studies using
ene knockout mice demonstrated that both CCR2 and
CP-1 deficiencies alleviate myocardial or renal IRI.6,8,9
oreover, the MCP-1/CCR2 axis displayed the role of
ontributing neutrophil recruitment through the cooperativ-
ty of monocyte in recent investigations, although neutro-
hils do not express CCR2 or respond to MCP-1 direc10
In the past decade, more and more studies have revealed
variety of cardiovascular benefits of 3-hydroxyl-3-
ethylglutaryl coenzyme A reductase inhibitors (statins)
eyond their well-known cholesterol-lowering property.11
hese so-called pleiotropic effects encompass anti-
nflammation, correction of endothelial dysfunction, in-
rease in nitric oxide bioavailability, antioxidation, and
tabilization of atherosclerotic plaques.12 Several mecha-
isms have been proposed for statin-elicited beneficial ef-
Abbreviations and Acronyms
CAL  coronary artery ligation
CCR2  CC chemokine receptor-2
GGPP  geranylgeranyl pyrophosphate
ELISA  enzyme-linked immunosorbent assay
IR  ischemia-reperfusion
IRI  ischemia-reperfusion injury
MCP-1monocyte chemoattractant protein-1
MPO myeloperoxidase
PCR  polymerase chain reactionects, including the prevention of mevalonate formation and a
The Journal of Thoracicubsequently the synthesis of isoprenoid farnesyl pyrophos-
hate and geranylgeranyl pyrophosphate (GGPP), which
eads to inhibition of the isoprenylation of small guanosine
riphosphate-binding proteins, such as Rho or Ras proteins
nvolved in cell differentiation, apoptosis, and inflammatory
esponse.11 More important, previous studies demonstrat
hat statins may significantly attenuate myocardial reperfusion
njury using a coronary artery ligation (CAL) model13,14 or
angendorff system.15 However, it is still not clear whet
RI in cardiac grafts may be ameliorated by perioperative
reatment of statins. In addition, recent in vitro studies
isplayed that simvastatin could down-regulate chemokine
eceptors CCR1, CCR2, and CCR5 expression.16 We there-
ore hypothesized that perioperative treatment of simvasta-
in could suppress the cardiac IRI by regulating MCP-1/
CR2 signaling in an inbred rat model of cardiac
ransplantation.
aterials and Methods
nimals and Groups
ll inbred male rats (200–250 g) were purchased from Vital River
td (Beijing, PR China). Lewis rats served as both donors and
ecipients. All animals received humane care in compliance with
he Principles of Laboratory Animal Care, formulated by the
ational Society of Medical Research, and The Guide for the Care
nd Use of Laboratory Animals, published by the U.S. National
nstitutes of Health (Publication No. 85-23, revised 1996). The
xperimental protocol described in this study was approved by the
ocal institutional ethical committee.
Rats were randomly divided into 3 groups: the control group
CON) (n  28), simvastatin-treated group (SIM) (n  28), and
ham group (n  24). In the first 2 groups, recipients were orally
dministrated vehicle (3 mL of saline) or simvastatin (Merck
harp and Dohme, Hangzhou, PR China, 1 mg/kg) every morning.
he dosage of simvastatin was described previously,17 which is
quivalent to 75 mg of simvastatin in humans. Drug administration
as begun 3 days before surgery and continued through the day of
eart harvest. The sham procedure consisted of anesthesia, abdom-
nal sectioning, and closure of the wounds.
urgical Procedure
he donor hearts were heterotopically transplanted into the abdo-
ens of recipients as previously described by Ono and Linds18
riefly, animals were anesthetized with an intraperitoneal injection
f pentobarbital (50 mg/kg). The donor was given heparin (1000
/kg), and cardiac arrest was induced in the donor heart by the
njection of ice-cold, high-potassium cardioplegia solution into the
ortic root. The procured hearts were quickly cooled in iced
eparinized saline. The recipient was not given heparin. The aorta
nd pulmonary artery of the donor heart were anastomosed end to
ide to the recipient abdominal aorta and inferior vena cava,
espectively. The grafts were consistently cooled during the pro-
edure with iced saline. We controlled the total cold ischemic time
f grafts for 45 minutes and the total ischemic time for 50 minutes
n each group. Cardiac isograft function was assessed by daily
bdominal palpation.
and Cardiovascular Surgery ● Volume 134, Number 3 781
S
I
a
w
l
T
p
t
p
t
a
a
s
i
I
I
c
d the
t
h
f
o
S
i
n
t
w
c
t
H
T
l
w
a so
d
m
i
t
l
w
D
M
l
s
h
s
O
4
i
q
D
i
M
u
f
w
g
C
R
T
R
t
a
R
c
(
t
r
t
r
N
e
v
f
a
s
s
P
P
M
L
(
S
A
D
w
W
p
g
g
a
M
h
n
R
I
R
g n-
t
f
2
H
E
A ntly
Cardiothoracic Transplantation Rong Yin et al
7
TXpecimen Collection
n each group, rats were sacrificed at 6 hours and at 1, 3, and 7 days
fter transplantation (n 6 in each time point). The blood samples
ere collected at the time of sacrifice for chemokines enzyme-
inked immunosorbent assay (ELISA) and cholesterol analysis.
he grafts were transversely sectioned into 2 portions. The basal
art was used for histologic and immunohistochemical examina-
ion. The remaining part was used for ELISA, myocardial myelo-
eroxidase (MPO) activity assay, and chemokine receptor quanti-
ative real-time polymerase chain reaction (PCR) analysis. In
ddition, in both the control and SIM groups, 4 isografts harvested
t 1 day after transplantation were randomly selected for infract
ize assessment. The specimens of sham group were obtained from
n situ hearts.
nfarct Size Assessment
nfarct size analysis was performed by 2, 3, 5-triphenyl tetrazolium
hloride staining (1% in phosphate buffer, pH 7.4) as previously
escribed.15 One day after transplantation, the rats were anes-
ized again and the abdomen was reopened. The hearts were
arvested and frozen at 20°C. Once solid, the hearts were sliced
rom apex to base into 5 to 7 sections and then incubated in 10 mL
f 2, 3, 5-triphenyl tetrazolium chloride at 37°C for 60 minutes.
ubsequently, the slices were destained for not less than 12 hours
n 10% formalin to increase the definition between viable and
onviable tissue. The slices were then photographed and planime-
ered using Image J (1.37v, NIH, Bethesda, MD). The area at risk
as then assessed as being the total ventricular volume (minus the
hamber spaces), and infarct size was expressed as a percentage of
he area at risk (infarct size/area at risk %).
istologic and Immunohistochemical Examination
he basal part of graft was placed in 10% phosphate-buffered forma-
in for at least 24 hours. At least four 4-m slides of each specimen
ere stained with Masson’s trichrome for evaluation of fibrosis grade,
s previously described.19 An immunohistochemical study was al
one on formalin-fixed, paraffin-embedded sections. The following
ouse-anti-rat monoclonal antibodies were used: ED1, a murine
mmunoglobulin-G1 anti-rat CD68 (macrophages/monocytes) (Sero-
ec, Oxford, UK, MCA341R); and HIS4, a murine immunoglobu-
in-M anti-rat neutrophil (Serotec, MCA967). Positively stained cells
ere counted by an investigator in a blind fashion.
etermination of Myeloperoxidase Activity
PO activity was determined as an index of neutrophil accumu-
ation in the IR myocardium as described previously.20 Myocardial
amples were homogenized in a phosphate buffer containing 0.5%
exadecyltrimethylammonium bromide. Samples were then as-
ayed for the ability to decompose H2O2 in the presence of
-dianisidine dihydrochloride by the change in absorption at
60 nm during 1 minute. The tissue MPO activity was expressed
n units per gram of wet tissue. One unit of MPO is defined as that
uantity of enzyme hydrolyzing 1 mol peroxide at 37°C.
etermination of Monocyte Chemoattractant Protein-1
n Serum and Isograft Tissue
CP-1 concentration in serum and isograft tissues was quantified
sing an ELISA kit specific for the rat chemokine per the manu- d
82 The Journal of Thoracic and Cardiovascular Surgery ● Septeacturer’s instructions (RapidBio Lab, Calabasas, Calif). Values
ere expressed as pictograms per milliliter for serum, and pico-
ram per 100 mg of protein for tissue samples.
CR2 mRNA Real-time Polymerase Chain
eaction Analysis
otal cellular RNA was isolated from cardiac tissue by using Trizol
eagents (Invitrogen Life Technologies, Carlsbad, Calif) according to
he manufacturer’s directions. RNA quality was insured by gel visu-
lization and spectrophotometric analysis (OD260/280). The quantity of
NA was measured using the OD260. RNA was transcribed to
DNA using Moloney murine leukemia virus reverse transcriptase
Promega, Madison, Wis) and oligo dT primers. Quantitative real-
ime PCR analysis was performed by using the Rotor-Gene 3000
eal-time DNA analysis system (Corbett Research, Sydney, Aus-
ralia), applying the real-time SYBR Green PCR technology. The
eaction mixtures contained diluted cDNA, SYBR Green I
ucleic Acid Stain (Invitrogen Life Technologies), and 20 M
ach gene-specific primer and nuclease-free water to a final
olume of 25 L. The PCR thermal cycle conditions were as
ollows: initial step at 9°C for 5 minutes, followed by 40 cycles
t 94°C for 20 seconds, 6°C for 20 seconds, and 7°C for 30
econds. Test cDNA results were normalized to -actin mea-
ured on the same plate. The primer was designed by using the
rimer Premier 5.0 program (PREMIER Biosoft International,
alo Alto, Calif).
easurement of Lipid Profiles in Plasma
ipid profiles were measured using an automated analyzer
Hitachi-917, Hitachi Ltd, Tokyo, Japan).
tatistical Analysis
ll results in the text are expressed as mean  standard deviation.
ata were analyzed using a commercially available statistics soft-
are package (Statistical Package for the Social Sciences for
indows v. 13.0, SPSS Inc, Chicago, Ill). Infarct size between
aired groups was analyzed by the Student paired t test. Fibrosis
rade, ED1, and HIS4-positive cells count between different
roups were analyzed by the Mann–Whitney U test. The 1-way
nalysis of variance was used to compare experimental data of
PO, real-time PCR, and ELISA between multiple groups. Post
oc comparisons were performed using the Tukey test or Dun-
ett’s T3 test.
esults
nfarct Size Data
epresentative slices of hearts from the control and SIM
roups are shown in Figure 1, A. One day after transpla
ation, simvastatin treatment significantly reduced the in-
arct size compared with the control group (26.65% 
.48% vs 41.46%  7.90%, P  .021, Figure 1, B).
istologic and Immunohistochemical
xamination Results
s shown in Figure 2, simvastatin treatment significa
ecreased the fibrosis grade at 7 days after transplantation
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TXompared with the control group (P  .004). At both 1
ay and 3 days after transplantation, the number of ED1-
ositive cells in the SIM group was markedly reduced
ompared with the control group (P  .009 and P  .002,
espectively). In addition, although the number of neu-
rophils was comparable between the control and SIM
roups (P  .394) 1 day after transplantation, neutrophil
nfiltration in the SIM group was significantly suppressed
ompared with the control group (P  .004) 3 days after
igure 1. A, Representative slices of hearts from the CON and
IM groups at 1 day after transplantation. Slices were stained
ith 2, 3, 5-triphenyl tetrazolium chloride. The risk but viable area
red ) and the infarct area (white-gray). B, Effects of simvastatin
n infarct size. Mean standard deviation, n 4 per group. *P<
05 versus control group. IS, Infarct size; AAR, area at risk.ransplantation. i
The Journal of Thoracicffects of Simvastatin on Myeloperoxidase Activity
n both the control and SIM groups, the MPO activity
radually increased, peaking 1 day after transplantation
efore gradually decreasing (Figure 3). At 1 day and 3
fter transplantation, the MPO activity in the SIM group
as reduced compared with the control group (P .01, P
049, respectively). However, no statistical significance was
eached at 6 hours and 7 days after transplantation.
ffects of Simvastatin on Monocyte Chemoattractant
rotein-1 Concentration in Serum and Isograft Tissue
s shown in Figure 4, A, the serum concentration of MCP
n the control group was rapidly elevated to a large extent at
hours after transplantation and gradually decreased at
ubsequent time points compared with the sham group. The
IM group had a similar time course and displayed signif-
cant reduction of MCP-1 level at all time points compared
ith the control group (P  .009, P  .02, P  .001, and
 .001, respectively). Similarly, the intragraft concentra-
ion of MCP-1 in the control group (Figure 4, B) was rapidly
levated at 6 hours after transplantation before starting to
ecrease gradually. In contrast, intragraft MCP-1 level in
he SIM group was suppressed and showed a delayed peak
day after transplantation in comparison with the control
roup. At the first 3 time points, the intragraft MCP-1 levels
ere markedly reduced in the SIM group compared with the
ontrol group (P  .001, P  .029, and P  .013,
espectively).
ffects of Simvastatin on CC Chemokine Receptor-2
RNA Expression
e analyzed intragraft chemokine receptor CCR2 mRNA
xpression by quantitative real-time PCR (Figure 5). 
sografts in control group displayed a significant up-regulation
n the expression of CCR2 compared with the sham group,
eaking at 6 hours after transplantation. The expression of
CR2 was similar between the SIM and the control groups
P  .697) at the first time point. Subsequently, CCR2
xpression in the SIM group was markedly down-regulated
ompared with the control group at 1, 3, and 7 days after
ransplantation (P  .001, P  .003, and P  .013,
espectively).
ipid Profiles of Plasma
reatment with simvastatin at our conditions did not signif-
cantly alter the plasma total cholesterol level (61.48 3.58
g/dL vs 64.26  4.39 mg/dL in the control group, P 
467), indicating that simvastatin-induced attenuation of IRI
as independent of its plasma cholesterol-lowering effects.
iscussion
he major findings of our study indicated that the periop-
rative administration of simvastatin significantly decreased
nfarct size and inflammatory cell infiltration of cardiac
and Cardiovascular Surgery ● Volume 134, Number 3 783
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TXsografts, resulting in attenuated IRI. Furthermore, simva-
tatin displayed the effects on reduction of MCP-1 level and
own-regulation of CCR2 expression, which may play a
ole in simvastatin-induced IRI suppression.
Increasing studies have revealed that the treatment of
nimals with statins attenuates myocardial IRI.13-15,21-26
owever, most of the studies were performed using the in
itro isolated perfused heart model (Langendorff system) or
he in vivo CAL model, which failed to address the issue
hether the heart transplantation recipients might benefit
rom the perioperative statin therapy. Both Langendorff and
AL models have disadvantages for the adequate evalua-
ion of this issue. The CAL model could only simulate
egional myocardial ischemia-reperfusion (IR) but not
lobal heart IR during transplantation, whereas the Langen-
orff system is performed in vitro and does not take the
Figure 2. Representative slices of donor hearts from CO
cell interstitial fibrosis (A) (Masson,200), macrophage
infiltration. Effects of simvastatin treatment on interstiti
at different time points. Mean  standard error of the m
.01 between control (open bars) and simvastatin (filledystem circulation and many peripheral complications into N
84 The Journal of Thoracic and Cardiovascular Surgery ● Septeccount, such as inflammatory cell infiltration. Furthermore,
he isolated heart rapidly deteriorates and often endures no
ore than 24 hours.27 Therefore, we used this model p-
ormed in vivo, which is closer to the clinical transplanta-
ion and persists for a longer time. Nonetheless, we cannot
ompletely simulate the clinical environment to obtain he-
odynamics data from this model.
Various methods were used by previous investigators with
egard to the administration protocol of statin. Most of the
tudies showed the protective effect of statin-administered
gents before the beginning of IR. However, the length of
retreatment time was different. Some investigators applied
tatins just several hours, 20 minutes, or 3 minutes before
schemia,14,24,28 or even at the onset of reperfusio22
cutely. Other studies used chronic treatment of statins for
 days,13 5 days,20 or even 3 weeks25 before the procedure
d SIM recipients. Simvastatin significantly attenuated
CD68 stain400), and neutrophil (C) (HIS4 stain,400)
rosis (D), macrophage (E), and neutrophil (F) infiltration
(SEM), n  6 rats per time point in each group. ##P <
s) groups, NS, Not significant.N an
(B) (
al fib
ean
barevertheless, a recent study of the Langendorff system
mber 2007
d
d
m to
s
g
i
t
e
t
t
o
c
m
a
o
l
c
w
m
a
p
v
o
p
t
F
a
3
M
#
F
M
t
M
p
M
c
t
C
Rong Yin et al Cardiothoracic Transplantation
TXemonstrated that pretreatment of atorvastatin for 1 or 3
ays significantly reduced the infarct size, whereas pretreat-
ent for 1 or 2 weeks failed.29 In this study, we planned 
imulate the clinical settings where the exact moment of
raft IR is usually indefinite; therefore, simvastatin admin-
stration was begun 3 days before operation and continued to
he end point. In our current experimental settings, the periop-
rative treatment of simvastatin displayed a significant reduc-
ion of infarct size and myocardial fibrosis grade at 1 day after
ransplantation, consistent with the previous findings.15,22
Neutrophil and macrophage recruitment is a key feature
f IRI. Gueler and colleagues30 revealed that short-term
erivastatin treatment significantly reduced ED1-positive
acrophage infiltration in a rat renal IR model. However, in
 mouse CAL model, Weinberg and colleagues13 failed to
bserve a marked change of neutrophil and CD45-positive
eukocyte infiltration between the rosuvastatin-treated and
ontrol groups at 1 and 2 days after surgery. In agreement
ith these findings, our study showed that ED1-positive
acrophage infiltration was also suppressed by simvastatin
t 1 day and 3 days after transplantation. However, HIS4-
ositive neutrophil accumulation was not obvious by sim-
astatin at 1 day after transplantation. Nevertheless, we still
bserved a significant reduction in the number of neutro-
hils 3 days after transplantation. Moreover, MPO activity,
igure 3. MPO activity in sham, CON, and SIM groups. MPO
ctivity in the SIM group was significantly decreased at 1 day and
days after transplantation compared with the control group.
ean  SEM, n  6 rats per time point in each group. *P < .05,
#P < .01 between CON and SIM groups.he quantitative index of neutrophil accumulation, has dis-
p
The Journal of Thoracicigure 4. Concentration of MCP-1 in serum and isografts. Both
CP-1 levels in serum and grafts were significantly elevated in
he CON group compared with the sham group. The serum level of
CP-1 was markedly decreased in the SIM group at each time
oint compared with the control group (A). The intragraft level of
CP-1 was not only decreased but also delayed in the SIM group
ompared with the control group (B). Mean SEM, n 6 rats per
ime point in each group. *P< .05, ##P< .01, **P< .001 between
ON and SIM groups. MCP-1, Monocyte chemoattractant
rotein-1.
and Cardiovascular Surgery ● Volume 134, Number 3 785
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7
TXlayed remarkable suppression at 1 day and 3 days after
ransplantation. Consequently, we believe that simvastatin
ay also alter neutrophil in addition to macrophage recruit-
ent at the later stage of reperfusion.
MCP-1 induces monocyte migration in vitro and plays a
ritical role in mononuclear cells recruitment in vivo, which
as been demonstrated.6 Tarzami and colleagues31 revealed
hat MCP-1 mRNA expression was increased after ischemia
nd peaked at 10 hours after ischemia, and that the MCP-1
rotein level in hypoxic-treated myocytes was also mark-
dly increased. Dewald and coworkers6,32 revealed that
CP-1 mRNA expression was rapidly induced at the early
tage of myocardial IRI, peaked at 6 hours after reperfusion,
nd gradually decreased to baseline at 3 days after reperfu-
ion in a mouse CAL model. Our study showed a similar
ime course of MCP-1 protein concentration in control
erum and isograft tissues. In addition, accumulating evi-
ence confirms that statins may suppress MCP-1 expression
oth in vitro and in vivo. However, most of the studies were
erformed in patients or animals with coronary artery dis-
ase33-35 or in endothelial cells and macrophages stimula
y tumor necrosis factor- or interferon-.16,36 Up to th
resent, few researchers have considered the effect of statins
n MCP-1 expression during IRI in transplantation, not-
igure 5. Quantitative real-time PCR of CCR2 mRNA expression in
ardiac isografts. The expression of CCR2 was significantly up-
egulated in the CON group, which was reversed in the SIM group
t 1, 3, and 7 days after transplantation. Mean  SEM, n  6 rats
er time point in each group. *P < .05, ##P < .01 between CON
nd SIM groups. CCR2, CC chemokine receptor-2.ithstanding that IRI and inflammation usually coexist in c
86 The Journal of Thoracic and Cardiovascular Surgery ● Septehe pathogenesis of coronary artery disease. In this study,
e observed that MCP-1 levels in either serum or tissue
ere remarkably decreased in the SIM group compared
ith the control group. We found that simvastatin not only
iminished the value of intragraft MCP-1 levels but also
elayed its peaking to 1 day after transplantation. Indeed,
uppression of macrophage infiltration should be the result
f the significant reduction of MCP-1.
Finally, we analyzed the intragraft expression of CCR2,
hich has been studied by many investigators. The latest in
ivo study37 demonstrated that CCR2 plays a critical r
or firm adherence of leukocytes under postischemic con-
itions and the recruitment of leukocytes to reperfused
issue at later time points. Dewald and colleagues6 also
eported that CCR2 showed a more prolonged induction
eaking at 72 hours after reperfusion in untreated wild-type
ice. However, our study found a different time course of
CR2 expression that peaked at 6 hours after transplanta-
ion, which was similar to the data reported by Tarzami and
olleagues.31 Nevertheless, these results displayed a p-
onged induction of CCR2 at the later phase of reperfusion.
ccumulating evidence has indicated that the blockade of
CR2 signaling or the use of CCR2 knockout mice may
lleviate left ventricular remodeling after myocardial in-
arction and myocardial or renal IRI.15,38 A recent study
sing 7ND-gene-transfection therapy significantly inhib-
ted MCP-1/CCR2 signaling and retarded renal IRI.39
onsequently, target CCR2 may undoubtedly provide a new
nsight for myocardial IRI therapy. Moreover, a recent in
itro study16 indicated that simvastatin down-regulated t
CR2 expression of human endothelial cells and macro-
hages. The authors concluded that the inhibition of
hemokine/chemokine receptors by simvastatin is GGPP-
ependent. The regulation of MCP-1 expression is related to
he inhibition of statins on geranylgeranylated members of
he Rho family guanosine triphosphatase. The activity of
ranscriptional repressor Oct-1 is also enhanced by statins
nd with a subsequent down-regulation of CCR2. In this
tudy, simvastatin did not display significant down-
egulation of CCR2 at 6 hours after transplantation, al-
hough the mean value of the SIM group was lower than
hat of the control group. We believe that although CCR2
xpression of recipient macrophages had been down-
egulated, the remnant leukocytes in the graft might up-
egulate CCR2 expression, which was insufficient to be
lleviated with the dosage of simvastatin within 6 hours.
owever, we observed a remarkable reduction of CCR2 at
he subsequent time points. Therefore, we considered that
imvastatin retards the MCP-1 secretion and CCR2 ex-
ression of macrophages simultaneously by the GGPP
athway, which is followed by the reduction of macro-
hage infiltration and further decreases the intragraft
oncentration of MCP-1. Furthermore, a previous study
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TXsing CCR2-deficient mice in a model of kidney IRI re-
uced the interstitial granulocyte infiltration.9 The authors
xplained that inflammation up-regulates CCR2 expression
n granulocytes and that MCP-1 and CCR2 promote the
hemotaxis of granulocytes during acute and chronic in-
ammatory conditions in vivo. Another independent inves-
igation also indicated that secondary generation of proin-
ammatory mediators by activated CCR2 monocytes is
uggested to subsequently promote the recruitment of neu-
rophils.10 Consequently, down-regulation of CCR2 an
CP-1 by simvastatin may partially contribute to the sup-
ression of both neutrophil and macrophage recruitment.
During the past 5 years, accumulating clinical studies
ave indicated that pretreatment of statins improves the
ostoperative prognosis and reduces the incidence of com-
lications associated with cardiac surgery.40 Therefore, it i
lausible for us to speculate that perioperative administra-
ion of statins initiated between 3 and 7 days before surgery
ay be beneficial for allograft survival. For example, the
xpected dosage of simvastatin may be approximately 40 to
0 mg per day for each transplant recipient. Furthermore,
espite our intriguing findings, several experimental limita-
ions were noted for this study. First, the donor hearts of
uman beings should not be preserved in the simple way we
escribed. Thus, heavy infarction could not emerge in the
linical settings, which may compromise the clinical rele-
ance of this study. Second, we failed to address whether
ositive results are demonstrated with a longer ischemic
uration in this study. Third, possible mechanisms involved
ere not exclusively investigated, such as the antioxidant
ffects and the ability of up-regulating endothelial nitric
xide synthase expression. Further study is warranted to
etter elucidate the signaling mechanisms involved and
ose-effectiveness relationship for simvastatin.
onclusions
ur experiment demonstrated for the first time that periop-
rative treatment of simvastatin suppressed myocardial IRI
ndependently of cholesterol-lowering effects in a rat model
f cardiac isograft transplantation. Our data revealed that
ttenuation of neutrophil and macrophage infiltration by
nhibiting CCR2 expression and reducing MCP-1 level may
erve as a possible mechanism of action for the protective
ffects elicited by simvastatin. On the basis of these find-
ngs, we speculated that perioperative treatment of statins
nitiated at 3 to 7 days before surgery may be beneficial for
eart allograft survival in the clinical setting.
The authors appreciate the technical assistance from Drs Gen-
ao Feng, Qui Meng, and Hao Ma.
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